Manuscripts -
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
JAMA
- Conclusion in summary: A dartboard would an equally effective to with which to designate Accelerated Approval status
ADC Business -
Drug Giant Tries New Tactic to Fight Cancer
Wall Street Journal
- Jose Baselga is directing AZ to focus on early stage cancer indications. Its a risky move because early stage is harder to detect, but maybe easier to treat. This shift might necessitate an early phase diagnostic technique in concert with the therapy
IPO boom: Antibody experts at Genmab outline global ambition in pitch for $500M
Endpoints News
- With a potential $500M payday, and two concurrent projects with SeaGen and a smaller partnership with ADC Therapeutics. Genmab is looking to become a major player in our space
Zymeworks' Lead Asset, ZW25, Granted Fast Track Designation from the FDA
Zymeworks
- Zymeworks is continuing its run of headline grabbing with a Fast Track Designation on its lead asset
Regulatory -
COTA and FDA Partner on Real-World Evidence Program in Breast Cancer
Biospace
- The FDA is taking a more wholistic view of cancer therapy with the help of COTA and real-world evidence. It is attempting to move beyond a single-minded view of Progression Free Survival times
In The Clinic -
Benefit of Antibody Drug Conjugate T-DM1 in HER2+ BC
TargetedOnc
- Sometimes its easy to forget how directly the ADC space impacts patients. If that weren't enough, this article proposes that preoperative application of T-DM1 can give indications about how to treat the patient after tumor removal via surgery
Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001
ADC Review
- Sutro is announcing the top-line results for their STRO-001 asset at the European Hematology Association conference. Initial reads look very encouraging.
Beyond the ADC World -
Trump pushed for the federal right-to-try law. One year later, only two people got treatment
Cincinnati Enquirer
- A perfect example of how a simple fix in the world of pharmaceuticals in anything but...
No comments:
Post a Comment